Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia (ASH) Basic Listing

Updates in Chronic Lymphocytic Leukemia
From the ASH Annual Meeting & Exposition

Ira L Zackon, MD
Conference Coverage
Evaluating Effects of Racial Disparities on the Treatment of Patients With Chronic Lymphocytic Leukemia
12/12/2023
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Jennifer Brown, MD
Conference Coverage
Extended Follow-up of ALPINE Study Confirms Zanubrutinib Yields Progression-Free Survival Benefit vs Ibrutinib for R/R CLL/SLL
12/11/2023
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Adrian Wiestner, MD
Conference Coverage
Analyzing Long-Term Outcomes of Ibrutinib Therapy for Patients With Chronic Lymphocytic Leukemia
12/11/2023
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
Importance of Assessing Minimal Residual Disease for R/R CLL Treatment
12/10/2023
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
Frontline Ibrutinib Plus Venetoclax Treatment Demonstrates Lasting Efficacy for Patients With CLL/SLL
12/10/2023
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Muhammad Bilal Abid, MD
Videos
AlloHSCT Outcomes From Younger Matched Unrelated Donors vs Older Sibling Donors for AML
01/25/2023
Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...
Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...
Muhammad Bilal Abid, MD,...
01/25/2023
Oncology
Conference Coverage
Tolerability and Efficacy of Azacitidine Plus Venetoclax Maintenance for Patients With AML
12/11/2022
Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.
Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.
Low-dose azacitidine plus...
12/11/2022
Oncology
Conference Coverage
Venetoclax Plus Azacitidine Sustains OS Benefit for Patients With AML Ineligible for Intensive Chemotherapy
12/11/2022
Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.
Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.
Long-term follow-up results from...
12/11/2022
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use